BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240304
DTEND;VALUE=DATE:20240306
DTSTAMP:20240201T221507Z
CREATED:20240201T221507Z
LAST-MODIFIED:20240201T221507Z
UID:59820-1709510400-1709683199@globalbiodefense.com
SUMMARY:Assessing the Burden and Potential Strategies to Address Antimicrobial Resistance
DESCRIPTION:A National Academies’ committee of experts will convene 4-5 March 2024 for a workshop to discuss the burden of antimicrobial resistance and strategies to address AMR challenges. \nParticipants can attend the workshop virtually and submit questions to speakers. The event will take place 12:00 PM – 4:15 PM ET each day. \nThere is broad recognition of the critical need to address the development and spread of antimicrobial resistance (AMR). A global\, systematic analysis estimates that AMR infections lead to 1.27-4.95 million deaths per year\, and resistant bacterial infections are now a leading cause of neonatal mortality worldwide. While scientific and economic challenges have long hindered development of novel antimicrobials\, recent pull incentives have been proposed to support a sustainable market and investment in new antimicrobials. These recent discussions provide a timely opportunity to explore the current burden of AMR and discuss potential future policies in the context of new scientific innovations. \nHighlighted agenda topics include: \nMonitoring AMR in Plants\, Animals\, and the Environment \n\nModerator: Ramanan Laxminarayan\, One Health Trust\nEnvironmental and Wastewater Surveillance: Joakim Larsson\, University of Gothenburg\nAMR in Livestock and Food Systems (or Crops): Paul Plummer\, Iowa State University College of Veterinary Medicine\nRole of AMR in Cross-cutting Conferences – Experience from COP28: Haileyesus Getahun\, World Health Organization\n\nMaking Meaning from Metrics: What’s at Stake? \n\nModerator: Chris Braden\, U.S. Centers for Disease Control and Prevention\nImpact of AMR – what’s not being captured: Dawn Sievert\, U.S. Centers for Disease Control and Prevention\nModeling Prevention Strategies: Joseph Lewnard\, University of California\, Berkeley\n\nImpact of AMR Across Medical Practice \n\nModerator: Helen Boucher\, Tufts University\nSkilled Nursing Facilities: Susan Huang\, University of California\, Irvine\nSurgery: Shawn Rangel\, Boston Children’s Hospital\nOncology: John Wingard\, University of Flo\n\nStewardship \n\nOutpatient or Telemedicine Perspective: Kristin Ray\, UPMC Children’s Hospital of Pittsburgh\nAdvanced Diagnostics: Robin Patel\, Mayo Clinic\nPediatric Antimicrobial Stewardship (Hospital Perspective): Ritu Banerjee\, Vanderbilt University Medical Center\n\nAccess \n\nProtecting Pharmaceutical Supply Chains in LMICs: Anthony McDonnell\, Center for Global Development\nImproving Access and Balancing Stewardship in LMICs: Jennifer Cohn\, Global Antibiotic Research & Development Partnership\nSustainable Use of Available Medicines: Esmita Charani\, University of Cape Town\n\nInnovation \n\nSynthetic Biology and Artificial Intelligence: James Collins\, Massachusetts Institute of Technology\nConsiderations for Successful Public-Private Partnership Model in Antibiotic Development: Ken Duncan\, Bill & Melinda Gates Foundation\nSupporting New Antimicrobials in Clinical Use: Ramy Elshaboury\, Massachusetts General Hospital\n\nPlease visit NASEM’s Assessing the Burden and Potential Strategies to Address Antimicrobial Resistance: A Workshop for more information. \n 
URL:https://globalbiodefense.com/event/assessing-the-burden-and-potential-strategies-to-address-antimicrobial-resistance/
LOCATION:https://www.nationalacademies.org/event/41831_03-2024_assessing-the-burden-and-potential-strategies-to-address-antimicrobial-resistance-a-workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240313
DTEND;VALUE=DATE:20240316
DTSTAMP:20240306T223831Z
CREATED:20240306T221528Z
LAST-MODIFIED:20240306T223831Z
UID:60523-1710288000-1710547199@globalbiodefense.com
SUMMARY:Antimicrobial Resistance – Genomes\, Big Data and Emerging Technologies
DESCRIPTION:Wellcome Genome Campus will host Antimicrobial Resistance – Genomes\, Big Data and Emerging Technologies on 13-15 March 2024 in Hinxton\, UK with onsite or virtual attendance. \nThis year’s programme will once again focus on genomic evidence and how to implement it in clinical practice and policy for antimicrobial resistance (AMR) control. The meeting will highlight the advances in machine learning\, AI and computational tools to predict AMR. We will also discuss how to build an international genomics infrastructure to tackle AMR and emerging lessons from other global public health issues. \nAMR is a major challenge in our globalised world\, and tackling it will take the combined resources and effort of researchers working across different disciplines. Technical advances in recent years continue to expand our ability to collect vast amounts of genomic information on pathogens\, and a wealth of data is being collected in epidemiological and surveillance studies\, including on the socio-economic burden of AMR. \nDiscussions will focus on a variety of exciting topics\, including: \n\nGenomic surveillance of priority pathogens\nGlobal public health pathogen genomics infrastructure\nTranslation and implementation of genomics for AMR control\nWastewater surveillance\nAI\, machine learning\, and big data tools\nMeasuring the burden of AMR\n\nPlease visit the Antimicrobial Resistance – Genomes\, Big Data and Emerging Technologies event page for more information.
URL:https://globalbiodefense.com/event/antimicrobial-resistance-genomes-big-data-and-emerging-technologies/
LOCATION:Wellcome Genome Campus\, Hinxton\, CB10 1SA\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240315T143000
DTEND;TZID=Europe/Paris:20240315T160000
DTSTAMP:20240306T225301Z
CREATED:20240306T223149Z
LAST-MODIFIED:20240306T225301Z
UID:60528-1710513000-1710518400@globalbiodefense.com
SUMMARY:COMBINE Webinar on Developing Target Product Profiles for Antibiotics
DESCRIPTION:The AMR Accelerator programme will host a COMBINE Webinar on Developing Target Product Profiles for Antibiotics on 15 March 2024. \nDecisions on disease targets and whether to aim for oral or intravenous administration of a new compound requires complex decisions\, involving the desires\, needs and expectations of patients\, healthcare organisations and regulators across the globe. \nDeveloping Target Product Profiles (TPP) is a challenge for antibiotics development. In this webinar\, speakers from CARB-X\, Evotec and GSK will discuss TPPs in relation to aims\, timing\, scope and flexibility. The discussion will discuss the need for TPPs across the development life-cycle: from drug discovery to clinical trials\, taking into account both clinical pathways\, the area of application and market considerations. \nPlease visit the COMBINE Webinar on Developing Target Product Profiles for Antibiotics event page for more information.
URL:https://globalbiodefense.com/event/combine-webinar-on-developing-target-product-profiles-for-antibiotics/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240317
DTEND;VALUE=DATE:20240323
DTSTAMP:20240306T224549Z
CREATED:20240306T224549Z
LAST-MODIFIED:20240306T224549Z
UID:60531-1710633600-1711151999@globalbiodefense.com
SUMMARY:Innovative Approaches in Antibacterial Research and Development to Fight the Antibiotic Resistance Crisis
DESCRIPTION:Innovative Approaches in Antibacterial Research and Development to Fight the Antibiotic Resistance Crisis will take place 17-22 March 2024 in Ventura\, CA. \nThe antibiotic resistance crisis is among us\, and with it\, the urgent need to tackle this global health threat has never been greater. Yet each step in the discovery and development process\, from target validation and inhibitor optimization to clinical trial design and product commercialization\, poses formidable challenges. The New Antibacterial Discovery and Development GCR will turn these challenges into opportunities to promote interdisciplinary innovation while addressing the global need for more effective antibiotic therapies. \nThe conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide\, concentrating on the latest developments in the field. \nHighlighted sessions include: \n\nDiscovering Mechanistically Novel Antibacterial Leads through Phenotypic Screening\nAntisense Antibiotics as Precision Therapeutics for Pseudomonas aeruginosa\nAddressing Antimicrobial Resistance in Clostridioides difficile: Clinical Implications and the Motivation for Novel Treatment Approaches\nBiasing Bacteriophage Behaviours\nAntibiotics Preorganized for Ribosomal Binding Overcome Antimicrobial Resistance\nHost Directed Therapy Against Mycobacterial Infections\nGARDP: Working Globally to Address the Antimicrobial Resistance Crisis\nBeta-lactamases and Skaters: Pairs and Singles\nDevelopment of Broad-Spectrum MBL Inhibitors\nSystems Chemical Biology Approach to Antibiotic Discovery\nMacrocyclic Peptides Disassemble the Periplasmic LPS Transport Bridge: New Approaches to Kill Multidrug-Resistant Gram-Negative Bacteria\nCracking Nature’s Recipes to Design Lipid-Targeting Antibiotics\nChallenges of Antibacterial Discovery\nGenerative Artificial Intelligence for Antibiotic Discovery\nMulti-Drug Resistant (MDR) Pathogens Are Driving the Need for New Novel Antibacterials\nReviving Natural Products Antibiotic Discovery\n\nPlease visit the Gordon Research Conference’s Innovative Approaches in Antibacterial Research and Development to Fight the Antibiotic Resistance Crisis website for more information.
URL:https://globalbiodefense.com/event/innovative-approaches-in-antibacterial-research-and-development-to-fight-the-antibiotic-resistance-crisis/
LOCATION:Ventura Beach Marriott\, 2055 Harbor Boulevard\, 2055 E Harbor Blvd\,\, CA\, 93001\, United States
END:VEVENT
END:VCALENDAR